Skip to main content
PMC home page
Gut logoLink to Gut
. 1984 Jul;25(7):707–710. doi: 10.1136/gut.25.7.707

Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.

C W Howden, J A Forrest, J L Reid
PMCID: PMC1432608  PMID: 6428981

Abstract

The effects of omeprazole, a substituted benzimidazole, on gastric acid and pepsin secretion have been studied in twelve healthy subjects. From six to eight hours after a single oral dose of 30 mg, there was a 66% reduction in basal acid output, and a 71.2% reduction in pentagastrin stimulated acid output. A single dose of 60 mg produced a 91.7% reduction in basal acid output and a 95.3% reduction in pentagastrin stimulated acid output. After seven days treatment with 30 or 60 mg daily, there was almost 100% inhibition of both basal and pentagastrin stimulated acid output. Omeprazole did not significantly affect pepsin secretion which is in keeping with its proposed mode of action, as an inhibitor of the H+/K+-ATPase enzyme on the secretory membrane of the parietal cell. There were no side effects after omeprazole either with single or repeated dosing.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berstad A. A modified hemoglobin substrate method for the estimation of pepsin in gastric juice. Scand J Gastroenterol. 1970;5(5):343–348. [PubMed] [Google Scholar]
  2. Blanchi A., Delchier J. C., Soule J. C., Payen D., Bader J. P. Control of acute Zollinger-Ellison syndrome with intravenous omeprazole. Lancet. 1982 Nov 27;2(8309):1223–1224. doi: 10.1016/s0140-6736(82)91246-6. [DOI] [PubMed] [Google Scholar]
  3. Burland W. L., Duncan W. A., Hesselbo T., Mills J. G., Sharpe P. C., Haggie S. J., Wyllie J. H. Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol. 1975 Dec;2(6):481–486. doi: 10.1111/j.1365-2125.1975.tb00564.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Faber R. G., Hobsley M. Basal gastric secretion: reproducibility and relationship with duodenal ulceration. Gut. 1977 Jan;18(1):57–63. doi: 10.1136/gut.18.1.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fellenius E., Berglindh T., Sachs G., Olbe L., Elander B., Sjöstrand S. E., Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature. 1981 Mar 12;290(5802):159–161. doi: 10.1038/290159a0. [DOI] [PubMed] [Google Scholar]
  6. Hassan M. A., Hobsley M. Positioning of subject and of nasogastric tube during a gastric secretion study. Br Med J. 1970 Feb 21;1(5694):458–460. doi: 10.1136/bmj.1.5694.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lind T., Cederberg C., Ekenved G., Haglund U., Olbe L. Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut. 1983 Apr;24(4):270–276. doi: 10.1136/gut.24.4.270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mason M. C., Giles G. R., Clark C. G. Continuous intravenous pentagastrin as a stimulant of maximal gastric acid secretion. Gut. 1969 Jan;10(1):34–38. doi: 10.1136/gut.10.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Müller P., Dammann H. G., Seitz H., Simon B. Effect of repeated, once daily, oral omeprazole on gastric secretion. Lancet. 1983 Jan 1;1(8314-5):66–66. doi: 10.1016/s0140-6736(83)91596-9. [DOI] [PubMed] [Google Scholar]
  10. Oberg K., Lindström H. Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazole. Lancet. 1983 Jan 1;1(8314-5):66–67. doi: 10.1016/s0140-6736(83)91597-0. [DOI] [PubMed] [Google Scholar]
  11. Peden N. R., Saunders J. H., Wormsley K. G. Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist. Lancet. 1979 Mar 31;1(8118):690–692. doi: 10.1016/s0140-6736(79)91146-2. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES